Section Arrow
NERV.NASDAQ
- Minerva Neurosciences
Quotes are at least 15-min delayed:2025/03/28 05:26 EDT
Last
 1.81
-0.055 (-2.95%)
Day High 
1.87 
Prev. Close
1.865 
1-M High
1.9104 
Volume 
3.43K 
Bid
1.72
Ask
1.9
Day Low
1.8 
Open
1.84 
1-M Low
1.42 
Market Cap 
13.04M 
Currency USD 
P/E 9.82 
%Yield -- 
10-SMA 1.71 
20-SMA 1.67 
50-SMA 1.94 
52-W High 3.69 
52-W Low 1.42 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.19/-2.68
Enterprise Value
13.04M
Balance Sheet
Book Value Per Share
-3.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Created with Highstock 5.0.121-min Chart13:3015:301.791.81.811.821.831.841.85etnet.com.hk@copyright
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 05:26 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.